Sumitomo Pharma revenue and financials
¥1,610.00Change from previous close: −0.68%Absolute change: −¥11.00
In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +352.17%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 23.6%
- FY to Mar 2025: 5.9%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | Q1 2026 | Q1 2025 |
|---|---|---|
| Total assets | 804,571 | 742,604 |
| Current assets | 279,252 | 253,168 |
| Cash and equivalents | 44,310 | 23,116 |
| Short-term investments | 5,327 | 16,840 |
| Inventory | 85,414 | 94,222 |
| Net property, plant and equipment | 44,231 | 46,648 |
| Goodwill | 211,098 | 197,406 |
| Other intangible assets | 160,474 | 172,509 |
| Long-term investments | 36,400 | 5,588 |
| Current liabilities | 271,500 | 240,603 |
| Accounts payable | 56,698 | 38,544 |
| Long-term debt | 179,056 | 258,982 |
| Total debt | 217,186 | 305,422 |
| Total liabilities | 512,104 | 573,125 |
| Total equity (incl. minority) | 292,467 | 169,479 |
| Retained earnings | 158,981 | 46,784 |
| Minority interest | — | 0.0 |